AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical ... has announced the completion of its acquisition of Nimble Therapeutics, a move aimed at strengthening its research and development pipeline ...
AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...
Second, with a strong focus on the immunology market, which, as I discussed in the article "Top 4 Immunology Stocks Poised ...
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...
Last month, AbbVie completed its acquisition of Nimble Therapeutics, and it also announced a partnership with Simcere Zaiming and expanded its collaboration with AbCellera. A stock popular with ...
In a separate development, AbbVie has completed the acquisition of Nimble Therapeutics, which is now integrated into AbbVie's operations. The oral peptide interleukin 23 receptor (IL23R ...
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.
The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
AbbVie (ABBV) and Xilio Therapeutics (XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...